Symbols / DCOY Stock $5.43 +0.09% Decoy Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
DCOY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Frederick E. Pierce II
Exch · Country NCM · United States
Market Cap 2.89M
Enterprise Value -7.82M
Income -12.52M
Sales —
FCF (ttm) 1.82M
Book/sh 11.07
Cash/sh 20.13
Employees 11
Insider 10d —
IPO Jan 29, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.28
PEG —
P/S —
P/B 0.49
P/C —
EV/EBITDA 1.91
EV/Sales —
Quick Ratio 2.07
Current Ratio 2.13
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -129.10
EPS next Y -19.32
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-31
Earnings (prior) 2026-03-31
ROA -36.36%
ROE -3.38%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 531.97K
Shs Float 528.44K
Insider Own 0.58%
Instit Own 12.42%
Short Float 4.37%
Short Ratio 0.79
Short Interest 23.25K
52W High 415.80
vs 52W High -98.70%
52W Low 5.20
vs 52W Low 4.33%
Beta 0.36
Impl. Vol. —
Rel Volume 0.32
Avg Volume 25.10K
Volume 8.12K
Target (mean) $30.00
Tgt Median $30.00
Tgt Low $30.00
Tgt High $30.00
# Analysts 1
Recom None
Prev Close $5.42
Price $5.42
Change 0.09%
About

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$30.00
Mean price target
2. Current target
$5.43
Latest analyst target
3. DCF / Fair value
$61.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.43
Low
$30.00
High
$30.00
Mean
$30.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-23 init Ladenburg Thalmann — → Buy $3
News
RSS: Latest DCOY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-30 HANISH ARNOLD C Director — 27 $0.64 $17
2025-11-20 ROSENBLUM MARK J Chief Financial Officer — 20,000 $0.80 $16,000
2025-11-20 HANISH ARNOLD C Director — 5,000 $0.75 $3,740
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.61
+119.97%
5.73
-55.53%
12.89
-43.87%
22.98
Research And Development
8.89
+1054.00%
0.77
-89.27%
7.17
-54.70%
15.84
Selling General And Administration
3.73
-24.91%
4.96
-13.23%
5.72
-19.85%
7.14
General And Administrative Expense
3.73
-24.91%
4.96
-13.23%
5.72
-19.85%
7.14
Other Gand A
3.73
-24.91%
4.96
-13.23%
5.72
-19.85%
7.14
Other Operating Expenses
—
—
—
—
Total Expenses
12.61
+119.97%
5.73
-55.53%
12.89
-43.87%
22.98
Operating Income
-12.61
-119.97%
-5.73
+55.53%
-12.89
+43.87%
-22.98
Total Operating Income As Reported
-12.61
-119.97%
-5.73
—
-31.84
EBITDA
-12.61
-120.02%
-5.73
+55.53%
-12.88
+43.90%
-22.97
Normalized EBITDA
-12.61
-120.02%
-5.73
+55.53%
-12.88
+8.73%
-14.12
Reconciled Depreciation
0.01
+61.64%
0.00
-55.98%
0.01
+50.53%
0.01
EBIT
-12.61
-119.97%
-5.73
+55.53%
-12.89
+43.87%
-22.98
Total Unusual Items
—
—
0.00
+100.00%
-8.85
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-8.85
Special Income Charges
—
—
0.00
+100.00%
-8.87
Impairment Of Capital Assets
—
—
0.00
-100.00%
8.87
Net Income
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Pretax Income
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Net Non Operating Interest Income Expense
0.10
-39.78%
0.16
-54.99%
0.35
+61.04%
0.22
Net Interest Income
0.10
-39.78%
0.16
-54.99%
0.35
+61.04%
0.22
Interest Income Non Operating
0.10
-39.78%
0.16
-54.99%
0.35
+61.04%
0.22
Interest Income
0.10
-39.78%
0.16
-54.99%
0.35
+61.04%
0.22
Other Income Expense
—
—
—
-8.85
Gain On Sale Of Security
—
—
—
0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Net Income From Continuing Operation Net Minority Interest
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Net Income From Continuing And Discontinued Operation
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Net Income Continuous Operations
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Normalized Income
-12.52
-124.52%
-5.58
+55.55%
-12.54
+44.88%
-22.76
Net Income Common Stockholders
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-129.10
+87.62%
-1,043.10
+81.15%
-5,533.20
+74.18%
-21,427.20
Basic EPS
-129.10
+87.62%
-1,043.10
+81.15%
-5,533.20
+74.18%
-21,427.20
Basic Average Shares
0.10
+1714.14%
0.01
+135.77%
0.00
+53.69%
0.00
Diluted Average Shares
0.10
+1714.14%
0.01
+135.77%
0.00
+53.69%
0.00
Diluted NI Availto Com Stockholders
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Line Item Trend 2023-12-31
Total Assets
6.59
Current Assets
6.52
Cash Cash Equivalents And Short Term Investments
5.90
Cash And Cash Equivalents
5.90
Receivables
0.00
Other Receivables
—
Prepaid Assets
0.47
Current Deferred Assets
0.00
Other Current Assets
0.15
Total Non Current Assets
0.07
Net PPE
—
Goodwill And Other Intangible Assets
—
Goodwill
—
Non Current Accounts Receivable
—
Other Non Current Assets
0.07
Total Liabilities Net Minority Interest
1.30
Current Liabilities
1.30
Payables And Accrued Expenses
1.01
Payables
0.60
Accounts Payable
0.60
Current Accrued Expenses
0.41
Current Debt And Capital Lease Obligation
0.29
Current Debt
0.29
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
0.00
Stockholders Equity
5.29
Common Stock Equity
5.29
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.00
Ordinary Shares Number
0.00
Treasury Shares Number
0.00
Additional Paid In Capital
81.64
Retained Earnings
-76.35
Total Equity Gross Minority Interest
5.29
Total Capitalization
5.29
Working Capital
5.22
Invested Capital
5.58
Total Debt
0.29
Net Tangible Assets
5.29
Tangible Book Value
5.29
Current Notes Payable
0.29
Dueto Related Parties Current
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-4.83
-6.67%
-4.53
+64.77%
-12.85
+26.99%
-17.60
Cash Flow From Continuing Operating Activities
-4.83
-6.67%
-4.53
+64.77%
-12.85
+26.99%
-17.60
Net Income From Continuing Operations
-12.52
-124.52%
-5.58
+55.55%
-12.54
+60.32%
-31.61
Depreciation Amortization Depletion
0.01
+61.64%
0.00
-55.98%
0.01
+50.53%
0.01
Depreciation
0.01
+61.64%
0.00
-55.98%
0.01
+50.53%
0.01
Depreciation And Amortization
0.01
+61.64%
0.00
-55.98%
0.01
+50.53%
0.01
Other Non Cash Items
8.52
—
—
1.99
Stock Based Compensation
0.22
-19.97%
0.27
-47.84%
0.52
-34.13%
0.80
Asset Impairment Charge
—
0.00
-100.00%
0.13
-98.53%
8.87
Operating Gains Losses
-0.01
—
—
-0.01
Gain Loss On Investment Securities
-0.01
—
—
-0.01
Change In Working Capital
-1.05
-235.49%
0.77
+179.75%
-0.97
-140.86%
2.37
Change In Receivables
—
0.00
-100.00%
1.48
0.00
Change In Prepaid Assets
0.42
-14.79%
0.49
-39.03%
0.81
+298.82%
0.20
Change In Payables And Accrued Expense
-1.47
-623.91%
0.28
+108.59%
-3.26
-250.26%
2.17
Change In Accrued Expense
-0.30
-450.20%
-0.05
+94.57%
-1.00
-217.15%
0.85
Change In Payable
-1.17
-449.27%
0.33
+114.81%
-2.26
-271.82%
1.31
Change In Account Payable
-1.17
-449.27%
0.33
+114.81%
-2.26
-271.82%
1.31
Investing Cash Flow
0.76
0.00
0.00
+100.00%
-1.50
Cash Flow From Continuing Investing Activities
0.76
0.00
0.00
+100.00%
-1.50
Net PPE Purchase And Sale
-0.58
0.00
—
—
Purchase Of PPE
-0.58
0.00
—
—
Capital Expenditure
-0.58
—
—
-1.50
Net Business Purchase And Sale
1.34
0.00
—
—
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-1.50
Purchase Of Intangibles
—
—
0.00
+100.00%
-1.50
Financing Cash Flow
12.34
+1064.00%
1.06
-84.04%
6.64
+234.09%
1.99
Cash Flow From Continuing Financing Activities
12.34
+1064.00%
1.06
-84.04%
6.64
+234.09%
1.99
Net Issuance Payments Of Debt
-0.22
+52.44%
-0.47
-66.07%
-0.28
0.00
Repayment Of Debt
-0.22
+52.44%
-0.47
-66.07%
-0.28
0.00
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Payments
-0.22
+52.44%
-0.47
-66.07%
-0.28
0.00
Net Short Term Debt Issuance
-0.22
+52.44%
-0.47
-66.07%
-0.28
0.00
Net Common Stock Issuance
12.56
+722.80%
1.53
-77.94%
6.92
+248.22%
1.99
Proceeds From Stock Option Exercised
—
—
—
0.00
Changes In Cash
8.28
+338.80%
-3.47
+44.17%
-6.21
+63.72%
-17.11
Beginning Cash Position
2.43
-58.74%
5.90
-51.27%
12.11
-58.56%
29.21
End Cash Position
10.71
+339.92%
2.43
-58.74%
5.90
-51.27%
12.11
Free Cash Flow
-5.40
-19.42%
-4.53
+64.77%
-12.85
+32.73%
-19.10
Interest Paid Supplemental Data
0.01
-45.50%
0.01
-27.86%
0.01
0.00
Common Stock Issuance
12.56
+722.80%
1.53
-77.94%
6.92
+248.22%
1.99
Issuance Of Capital Stock
12.56
+722.80%
1.53
-77.94%
6.92
+248.22%
1.99
Sale Of Business
1.34
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category